CHICAGO: Suven Life Sciences Ltd said a drug being developed by the company to treat Alzheimer’s disease is now being tested in multiple doses among volunteers, having passed the single-dose stage.
Suven said that the drug candidate called SUVN-G3031 is undergoing a so-called Phase-1 study in the US, which evaluates its safety and tolerability, among other traits…